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Introduction
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic dis-
ease characterized by extraskeletal bone formation in soft tissue, 
where bone normally does not exist. Ectopic bones are formed 
through endochondral ossification, a process in which bone tis-
sue replaces mature cartilage (1–7). Patients with classic FOP 
have a 617G>A (R206H) point mutation in the intracellular gly-
cine- and serine-rich (GS) domain of ACVR1 (8), a type I receptor 
for BMPs (9–18). This mutation has been shown to render ligand- 
independent constitutive activity and ligand-dependent hyper-
activity in BMP signaling (19–21). The vast majority of drug can-
didates for FOP treatment suppress the abnormal activation of 
BMP signaling. Examples include direct kinase inhibitors of the 
catalytic domain of BMP type I receptors, such as dorsomorphin, 
LDN-193189, DMH1, RK-0071142, ML357, LDN-212854, and 
K0288, which consequently suppress the phosphorylation of the 
downstream effectors SMAD1/5/8 (22–27); RARγ agonists, which 
reduce the expression of SMAD1/5/8 by protein degradation (28); 
allele-specific RNAi (ASP-RNAi) that target mutated ACVR1 (FOP-
ACVR1) mRNA for degradation (29, 30); inhibitors of hypoxia- 
inducible factor-1α (HIF1α), which prevent the formation of mes-
enchymal condensations (31) or amplification of BMP signaling 
(32); and others (33, 34). Among these drug candidates, only palo-
varotene (28, 35–37), a RARγ agonist, is now in clinical trial.
Recently, we and Hatsell et al. discovered a mechanism of het-
erotopic ossification (HO) by using FOP patient–derived induced 
pluripotent stem cells (FOP-iPSCs) and FOP-ACVR1 conditional- 
on knockin mice (38, 39). These studies revealed that mutated 
FOP-ACVR1 abnormally transduces BMP signaling in response 
to Activin-A, a molecule that normally transduces TGF-β sig-
naling but not BMP signaling. This neofunction of Activin-A 
raised the possibility that the inhibition of Activin-A signaling by 
Activin-A–specific–neutralizing antibody or by broad-acting BMP 
and Activin blockers like ACVR2A-Fc and ACVR2B-Fc (38–42) 
could be a new treatment strategy for FOP. Although Activin-A 
evoked enhanced chondrogenesis of induced mesenchymal stro-
mal cells derived from FOP-iPSCs (FOP-iMSCs) via BMP and 
TGF-β signaling (38, 43), the detailed mechanism, especially 
downstream effectors of Activin-A/FOP-ACVR1, is largely unex-
plained. Therefore, dissecting the molecular mechanisms of this 
cascade could lead to promising therapeutic strategies.
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monitor the degree of enhanced chondrogenesis in HTS format 
(384 wells). Inhibition of either BMP signaling or TGF-β signal-
ing with a specific inhibitor (DMH1 or SB-431542, respectively) 
showed reduced luciferase activity, indicating the pivotal roles of 
both signaling pathways in chondrogenesis. These data confirmed 
that the HTS assay we developed can evaluate the enhanced chon-
drogenesis of FOP-iMSCs stimulated by Activin-A.
HTS and follow-up screens of FOP-iPSCs highlight mTOR sig-
naling as a candidate pathway for modulating enhanced chondro-
genesis in FOP. Using this luciferase-based HTS system (5×A-Luc 
assay), we performed a first screening (n = 1; test compounds 
= 1 μM) against our HTS library, which contains approximately 
7,000 small-molecule compounds, most of which are bioactive 
and annotated (Figure 2A, Table 1, and Supplemental Figure 1, 
A and B; supplemental material available online with this article; 
https://doi.org/10.1172/JCI93521DS1). The scatter plot distribu-
tion (Figure 2B), histogram of raw data (Figure 2C), Z-factor, and 
signal-to-background (S/B) ratio (Supplemental Figure 1, C and 
D) confirmed the validity of the HTS campaign. From the first 
screening, we obtained 549 hit compounds that showed more 
than 40% inhibition of luciferase activity against DMSO control 
cells stimulated with Activin-A. RARγ agonists and dorsomorphin 
were identified as positive chemicals, indicating the accuracy of 
our HTS system. A second screening was performed against these 
549 compounds (n = 2; test compounds = 0.01, 0.1, and 1 μM), and 
we identified 76 hit compounds that showed an IC50 of less than 1 
μM in the 5×A-Luc assay and low cytotoxicity in the alamarBlue 
assay (inhibition of <20% at any dose) (Supplemental Figures 2 
and 3 and Table 2). In the classification of these 76 hit compounds, 
we found several reported compounds, such as corticosteroids 
(22, 35), RAR agonists (28, 35–37), and ALK5 inhibitor (38), that 
To this end, we established an iPSC-based high-throughput 
screening (HTS) system using FOP-iMSCs and Activin-A–induced 
enhanced chondrogenesis (38, 44, 45) and used it to screen our HTS 
library, which contains approximately 7,000 small-molecule com-
pounds. This screening led us to identify mTOR signaling as a criti-
cal downstream pathway of FOP-ACVR1 in enhanced chondrogen-
esis, an essential step of HO in the pathology of FOP. Rapamycin, a 
commercially available drug and commonly used mTOR inhibitor 
(46–48), showed potent therapeutic effects on HO in 2 different in 
vivo models triggered by Activin-A: FOP model mice expressing 
FOP-ACVR1 and an FOP-iPSC–based HO model, in which ectopic 
bones derived from FOP patient–derived cells are formed in mice. 
We also identified ENPP2 (also known as autotaxin) as an upstream 
molecule that positively regulates the mTOR activity triggered 
by Activin-A. These data uncovered a molecular basis for the HO 
induced in patients with FOP.
Results
Development of an HTS system focused on enhanced chondrogenesis of 
FOP-iMSCs. Ectopic chondrogenesis is a critical step of endochon-
dral heterotopic ossification in FOP patients (1–6), and enhanced 
chondrogenesis of FOP-iMSCs was observed when cells were 
stimulated with Activin-A in vitro and in vivo (38). Therefore, to 
monitor the degree of enhanced chondrogenesis, an HTS system 
was established using FOP-iMSCs stably harboring luciferase fol-
lowing 5-repeats Aggrecan enhancers, a well-established chon-
drogenesis marker (7, 49) (FOP-5×A-Luc-iMSCs; Figure 1A). As 
expected, the induction of chondrogenesis with Activin-A stimu-
lation in a 384-well plate increased luciferase activity in FOP-5×A-
Luc-iMSCs (Figure 1B). Next, we confirmed the expression level of 
Aggrecan mRNA (ACAN), the glycosaminoglycan (GAG) produc-
tion to DNA ratio (GAG/DNA), which represents the extracellular 
matrix amount of chondrocytes, and Alcian blue staining (acidic 
polysaccharides such as GAG in chondrocytes) in a 2D chondro-
genesis induction (2DCI) assay using FOP-5×A-Luc-iMSCs (Fig-
ure 1, C–E). Consistent with the luciferase assay (5×A-Luc assay), 
Activin-A stimulation increased these values in the 2DCI assay. 
Therefore, we concluded that the 5×A-Luc assay could be used to 
Table 1. Source and number of compounds in the HTS library
Library name Supplier Number
Enzo FDA Enzo Life Sciences 636
Enzo ICCB Enzo Life Sciences 474
Enzo Kinase Inhibitors Enzo Life Sciences 76
LOPAC1280 Sigma-Aldrich 1,280
Sigma Pfizer Sigma-Aldrich 74
Myriascreen TimTec 72
MicroSource International Drugs MicroSource Discovery Systems 238
MicroSource US Drugs MicroSource Discovery Systems 1,020
EMD Kinase Inhibitors Merck Millipore 244
Selleck Kinase Inhibitors Selleck Chemicals 141
Tocris Mini Selected for CiRA Tocris Bioscience 637
Natural Products Analyticon Discovery 1,917
Total  6,809
Table 2. Classification of 76 hit compounds through the second 
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caused by toxicity. These rapamycin effects were also confirmed 
in a BMP-7–induced HO model using WT mice and also with 
another mTOR inhibitor, everolimus (Supplemental Figure 6 and 
Supplemental Tables 2 and 3). These results indicated that mTOR 
inhibition was effective at suppressing HO in FOP model mice.     
Rapamycin suppresses HO derived from FOP-iPSCs in vivo. In 
both basic and clinical research, species differences are often 
reported (52–54) and hamper the study of the disease mechanism 
in humans. To overcome this problem, in vitro and ex vivo assays 
using patient-derived tissue or iPSCs have been used, but the in vivo 
assay using human cells remains highly challenging. We previously 
reported an FOP patient–derived iPSC–based in vivo FOP model, in 
which ectopic bones derived from FOP-iPSCs were formed in mice 
(38). In the present study, we evaluated the significance of mTOR 
signaling in this model. The transplantation of FOP-iMSCs into the 
gastrocnemius muscle of NOD/SCID mice with C3H10T1/2 cells 
harboring Dox-inducible Activin-A showed HO when the mice 
were administrated Dox (Figure 5, A and B, and Table 5). As with 
the FOP-ACVR1 conditional transgenic mice, we observed safr-
anin O–, von Kossa–, and COL1-positive cells, suggesting extraskel-
etal bone formation through an endochondral process (Figure 5C). 
Interestingly, i.p. or oral administration of rapamycin suppressed 
the HO triggered by Activin-A (Figure 5, Table 5, Supplemental 
Figure 7, A and B, and Supplemental Table 4). Since we observed 
a large number of anti-human–specific vimentin-positive cells in 
the rapamycin-treated group (Figure 5C), it seemed that the role of 
rapamycin in this model was not to kill the human cells but rather 
to suppress HO itself. Moreover, HO was suppressed, even when 
rapamycin treatment was started 2 weeks after transplantation and 
Dox administration (Supplemental Figure 7, C and D, and Supple-
mental Table 5); therefore, a window of opportunity for HO sup-
pression would occur not before Activin-A is secreted, but rather 
after its secretion, when the Activin-A signal has been initiated to 
some extent. Taken together, rapamycin suppressed FOP-iPSC–
derived extraskeletal bone formation in vivo, and mTOR inhibition 
was effective at suppressing HO in both FOP mouse models.
Enhanced mTOR signaling in chondrogenic induction of FOP- 
iMSCs. Although mTOR inhibition was effective at suppressing 
HO in vivo, the detailed mechanism was unclear. To clarify the 
critical role of mTOR signaling and its key components in the 
chondrogenic induction of FOP-iMSCs, we performed a loss-of- 
function study using siRNA. MTOR knockdown decreased GAG/
DNA (Figure 6A) and Alcian blue staining (Figure 6B) in 2DCI 
assays of FOP-iMSCs, demonstrating the essential role of mTOR 
signaling. It is known that mTOR, a serine/threonine protein 
kinase, forms the catalytic subunit of 2 different protein com-
were effective for FOP. Among these, we focused on mTOR sig-
naling, because 5 mTOR inhibitors were identified, suggesting 
the feasibility of mTOR inhibition in this assay system. In partic-
ular, rapamycin and its analogs showed potent inhibition in the 
5×A-Luc assay, even at 10 nM (Supplemental Figure 2). Further-
more, the significance of mTOR signaling in FOP pathology has 
not been well studied.
Next, we performed a detailed concentration-dependent 
assay against mTOR inhibitors (rapamycin, everolimus, and tem-
sirolimus) using the 5×A-Luc assay. These 3 compounds showed 
potent IC50 values (Figure 3A and Table 3). To determine whether 
they actually restore the enhanced chondrogenesis of FOP-iMSCs 
triggered by Activin-A, we performed 2D and 3D chondrogene-
sis induction (3DCI) assays. In both assays, these 3 compounds 
showed potent inhibition of GAG/DNA (Figure 3, B and C, and 
Table 3), Alcian blue staining (Figure 3, D and E), and expression 
of chondrogenesis markers (Supplemental Figure 4). Rapamycin 
showed the strongest IC50 value in these 3 assays; therefore, we 
performed further analyses mainly using rapamycin. These data 
indicate that mTOR inhibitors show potent effects on the chon-
drogenesis of FOP-iMSCs enhanced by Activin-A.
Rapamycin suppresses HO in FOP-ACVR1 conditional transgenic 
mice. Although rapamycin is reported to prevent both trauma- 
induced and genetic HO (31), its effect on FOP model mice, par-
ticularly on mice with Activin-A–induced HO, is unknown. To 
evaluate the importance of mTOR signaling in FOP model mice, 
we generated human FOP-ACVR1 (R206H) conditional trans-
genic mice (Figure 4A and Supplemental Figure 5A). These mice 
conditionally express FOP-ACVR1 by doxycycline (Dox) admin-
istration and are able to escape the perinatal lethality seen in 
FOP-Acvr1 heterozygous mice (50). Three weeks after Activin-A 
injection into the right gastrocnemius muscle and induction of 
FOP-ACVR1 by Dox administration, we observed HO formation 
in the injected site (Figure 4, B and C, and Table 4). In the 
injected site, we observed positive staining for safranin O (acidic 
proteoglycan, an extracellular matrix protein of chondrocytes), 
von Kossa (calcium deposition), and COL1 (bone marker), impli-
cating that heterotopic bones were formed through endochondral 
ossification (Figure 4D). On the contrary, mice administered rapa-
mycin showed little or no heterotopic bone formation. Further-
more, rapamycin administration suppressed the HO triggered 
by cardiotoxin (Supplemental Figure 5, B–D, and Supplemental 
Table 1). In these experiments, rapamycin administration did not 
decrease BW (Supplemental Figure 5, E and F), and the dosing 
used was comparable to standard rapamycin dosing in humans 
(51), indicating that the HO suppression might not be mainly 
Table 4. Number of FOP-ACVR1 conditional transgenic mice 
harboring HO (>20 mm3 bone volume) triggered by Activin-A 
(related to Figure 4)
Compound No. of HOs (>20 mm3)
Vehicle 9/11
Rapamycin 0/11
Table 3. IC50 values for everolimus, rapamycin, and temsirolimus 
in 5×A-Luc assay, 2DCI assay, and 3DCI assay (related to Figure 3)
IC50 Everolimus Rapamycin Temsirolimus
5×A-Luc 6.2 nM 0.4 nM 0.5 nM
2DCI 1.2 nM 0.2 nM 0.7 nM
3DCI 3.1 nM 0.5 nM 1.1 nM
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ure 6, A and B). These data indicated a critical role of mTORC1, 
but not mTORC2, signaling in the 2DCI assays on FOP-iMSCs 
stimulated with Activin-A. We previously showed that in FOP-iM-
SCs, Activin-A transduces BMP signaling in addition to TGF-β 
signaling and that inhibition of either signal suppresses enhanced 
chondrogenesis in FOP-iMSCs (38) (Figure 1, B–E). Therefore, 
to determine whether rapamycin directly inhibits either BMP 
or TGF-β signaling, we performed Western blotting to analyze 
the phosphorylation of SMAD1/5/8 (cytoplasmic BMP signaling 
transducers) and SMAD2/3 (cytoplasmic TGF-β signaling trans-
ducers). Rapamycin did not directly inhibit BMP (Figure 6C) or 
TGF-β signaling (Figure 6D). Moreover, we found an upregulation 
of mTORC1 activity triggered by Activin-A during chondrogenesis 
in FOP-iMSCs compared with that observed in mutation-rescued 
FOP-iMSCs (resFOP-iMSCs), in which the mutant ACVR1 was 
converted to WT (45). Phosphorylation of S6 (p-S6), a surrogate 
marker of mTORC1 activity (55–59), was enhanced in FOP-iMSCs 
plexes, mTOR complex 1 (mTORC1, a rapamycin-sensitive com-
plex) and mTOR complex 2 (mTORC2, a rapamycin insensitive 
complex), to orchestrate diverse functions (55–59). Therefore, 
we analyzed the importance of these complexes in chondrogen-
esis. As expected, we found that knockdown of RPTOR, a major 
component of mTORC1, decreased GAG/DNA and Alcian blue 
staining, but not RICTOR, a major component of mTORC2 (Fig-
Figure 1. Construction and characterization of the FOP-5×A-Luc assay 
system. (A) Construction of FOP-5×A-Luc-iPSCs. Luciferase, following 
the COL2A1 promoter and 5-repeats Aggrecan enhancer (5×A), was 
inserted into the pTrans1-3 vector to produce stably expressing cell lines 
by using Tol2 transposase from Japanese medaka fish. After cotrans-
fection with pCAGGS-mT2TP (Tol2 transposase expression vector), the 
neomycin-resistant clone was selected and designated as FOP-5×A-
Luc-iPSC. (B–E) Characterization of FOP-5×A-Luc-iMSCs. Luciferase 
activity (B), Aggrecan (ACAN) expression levels (qPCR analysis) (C), 
GAG/DNA ratios (D), and Alcian blue staining (E) of 2DCI assays. The 
cells were harvested 3 days (B), 7 days (C), or 6 days (D and E) after 
chondrogenesis induction was performed, with or without Activin-A 
and inhibitors (10 μM). Data represent the mean ± SEM. n = 4 (B–D). 
***P < 0.001, by Dunnett’s multiple comparisons t test compared with 
the DMSO treatment control with Activin-A (B–D).Representative data 
of n =3. Scale bar: 200 μm (E). SB, SB-43152.
Table 5. Number of mice harboring HO (>20 mm3 bone volume) 
derived from FOP-iPSCs in vivo (related to Figure 5)
Compound No. of HOs (>20 mm3) 
Vehicle 5/5
Rapamycin 0/4
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es, and is known to activate mTOR signaling through LPA 
receptors (60, 61). The administration of ENPP2 inhibi-
tors (HA130 and PF-8380) (Figure 7D) or knockdown of 
ENPP2 by siRNAs (Figure 7E) decreased the level of p-S6 
induced by Activin-A. ENPP2 inhibitors also suppressed 
GAG/DNA in 2DCI assays of FOP-iMSCs stimulated by 
Activin-A (Supplemental Figure 10). Conversely, LPA 
treatment increased p-S6 levels in FOP-iMSCs (Figure 
7F). Taken together, these results indicate that ENPP2 
is an upstream regulator of the enhanced mTORC1 sig-
naling triggered, at least partially, by Activin-A in FOP- 
iMSCs although further study is required for a more 
detailed understanding of the underlying mechanism.
Discussion
In this report, we clarified that mTOR signaling was 
enhanced in the chondrogenesis of FOP-iMSCs as com-
pared with resFOP-iMSCs and that this aberrant signal was 
regulated by the Activin-A/FOP-ACVR1/ENPP2 cascade. 
It is known that mTOR signaling coordinates a variety of 
environmental inputs including energy, nutrients, stress, 
and growth factors. Thus, the dysregulation of mTOR sig-
naling, i.e., the abrogation of homeostasis, causes many 
disorders including cancer, diabetes, neurodegeneration, 
and others (47, 48, 55–59). Rodgers et al. proposed that 
mTORC1 controls tissue regeneration by activating quies-
cent stem cells into an “alert state” to respond rapidly under condi-
tions of injury and stress (62, 63). In FOP pathology, the mutation 
of ACVR1 appears to deviate this fine-tuned tissue homeostasis 
mechanism. Activin-A is strongly expressed in wounded regions 
and promotes the regeneration of damaged tissue (64–66). In FOP, 
however, we found what we believe to be a new signaling pathway 
for Activin-A that initiates HO formation by mistransducing BMP 
signaling. MSCs, which are cells of origin of HO in FOP (67, 68), 
respond abnormally to an Activin-A–evoked signal by taking on an 
osteo/chondrogenic lineage that is consistent with the response to 
bone fracture. Because Activin-A activates mTOR signaling in FOP, 
this response by MSCs could be related to the alert state. Rodgers et 
al. also showed that HGF signaling is necessary for transition to the 
alert state as a putative upstream regulator of mTORC1 signaling. On 
the other hand, we show that ENPP2-mediated mTORC1 activation 
is the key event in aberrant chondrogenesis. These observations sug-
gest that mTOR signaling is precisely regulated by the cell type and 
stimulant. To fully understand mTORC1 signaling in the enhanced 
chondrogenesis of FOP, it is necessary to investigate the downstream 
effectors of mTORC1. Furthermore, as we previously discussed 
(38), because Activin-A does not bind to GREM, an inhibitor of 
BMPs (14, 16, 69) that is upregulated in FOP-iMSCs stimulated with 
Activin-A, BMP signaling does not properly negatively regulate 
Activin-A. Given these results, we propose that the mechanistic 
cause of FOP pathology involves the activation of mTOR signaling 
by Activin-A and the failed negative regulation by BMP signaling.
Although much research has been devoted to mTOR signal-
ing, there are a limited number of reports about the relationship 
between mTOR signaling and chondrogenesis. During chicken 
embryonic development, the mechanical activation of mTOR is 
required for chondrocyte proliferation and chondrogenesis during 
compared with resFOP-iMSCs stimulated by Activin-A during the 
2DCI assay (Figure 6E and Supplemental Figure 8). Finally, to 
evaluate the signaling cascade of activated mTORC1 signaling, we 
assessed several inhibitors, including LY294002 (PI3K inhibitor), 
ipatasertib (AKT inhibitor), and BIRB 796 (p38MAPK inhibitor). 
In addition to rapamycin, we found that LY294002 and ipatasert-
ib, but not BIRB 796, inhibited the Activin-A–induced phosphor-
ylation of S6 (Figure 6F). These data indicated an involvement of 
the PI3K/AKT/mTORC1 cascade. Taken together, our findings 
show that Activin-A activates mTORC1 signaling during chondro-
genesis to a greater extent in FOP-iMSCs than in resFOP-iMSCs 
and that mTORC1 activity is regulated by PI3K/AKT signaling.
ENPP2-mediated enhanced mTOR signaling in chondrogenic 
induction of FOP-iMSCs. Next, to gain insight into the molecular 
mechanisms underlying the enhanced chondrogenesis observed 
in FOP-iMSCs, we performed an unbiased transcriptome analy-
sis using a DNA microarray. Interestingly, we found that mTOR 
pathway–related genes were significantly changed in FOP-iMSCs 
compared with resFOP-iMSCs 24 hours after chondrogenesis 
induction with Activin-A, but not with BMP-7 or TGF-β3 (Supple-
mental Figure 9). Therefore, Activin-A regulated mTOR signaling 
in the chondrogenesis of FOP-iMSCs by acting on global gene 
expression levels. Next, we explored the upstream regulators of 
mTORC1. Among the genes upregulated in FOP-iMSCs 24 hours 
after chondrogenesis induction with Activin-A but not with BMP-7 
or TGF-β3 (Figure 7A), we found that ENPP2 was the most differen-
tially expressed gene (Figure 7B). ENPP2 expression was increased 
after Activin-A–stimulated chondrogenesis induction, particularly 
in FOP-iMSCs (Figure 7C). ENPP2 is a secreted lysophospholipase 
D that generates the lipid mediator lysophosphatidic acid (LPA), 
plays a key role in diverse physiological and pathological process-
Figure 2. Identification of mTOR inhibitors through HTS. (A) Schematic of the HTS 
and follow-up screens. (B and C) Raw data from the first screening against 6,809 
compounds. Scatter plot distribution (B) and histogram (C) of the percentage of 
inhibition data. Detailed protocol information and data are provided in Methods and 
the Supplemental figures.
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bone development (70). In mouse embryos, mTORC1 signaling is 
activated during limb cartilage development, and the disruption of 
mTORC1 signaling diminishes embryonic skeletal growth, causing 
severe delays in chondrocyte hypertrophy and bone formation (71). 
Furthermore, a reduction in cell size and the amount of cartilage 
matrix, without changes in chondrocyte proliferation or survival, 
cause a reduction in the growth of cartilage (71). Both the chicken 
and mouse studies suggest that mTOR signaling positively mod-
ulates chondrogenesis, albeit by distinctive mechanisms. These 
observations support the notion that mTOR signaling promotes 
chondrogenesis and are mostly consistent with our study, which 
showed that mTOR inhibition potently suppressed the enhance-
ment of chondrogenesis in FOP-iMSCs or HO in vivo (Figures 
3–5 and Supplemental Figures 4–7). In our 2D and 3DCI assays 
of Activin-A–stimulated FOP-iMSCs, mTOR inhibitors clearly 
decreased both GAG/DNA and the expression levels of chondro-
genesis markers (Figure 3 and Supplemental Figure 4), indicating 
that mTOR inhibition did not simply affect proliferation or survival, 
but modified the differentiation of chondrocytes, since data from 
both assays were corrected by the number of cells (DNA amount) 
and the expression of a housekeeping gene (β-actin), respectively. 
On the other hand, another report showed that hyperactivation of 
mTORC1 via TSC1 gene deletion in chondrocytes blocked chondro-
cyte differentiation (72). These reports 
suggest that a well-coordinated, but 
complicated, regulation of mTORC1 
activity is crucial for chondrocyte 
differentiation during development. 
Further study is needed to clarify the 
phase of endochondral ossification in 
which mTOR signaling is activated and 
when mTOR signaling should be inhib-
ited to suppress HO. Such investigation 
will lead to a deeper understanding of 
FOP pathology and the discovery of 
new therapeutic targets.
The establishment of an iPSC-
based HTS system is one of the features 
of this study (Figures 1 and 2, Tables 
1 and 2, and Supplemental Figures 
1–3). Although HTS would be of much 
greater benefit with patient-derived 
iPSCs, such an adaptation remains 
challenging because of unstable pro-
tocols and/or long culture periods for 
differentiation. Although many path-
ways are involved in chondrogenesis 
(7), our HTS-based system enabled 
us to select the pathways crucial for 
modulating chondrogenesis. We iden-
tified mTOR inhibitors as effective 
drug candidates and confirmed their 
efficiency with multiple in vivo HO 
models (Figures 4 and 5, and Supple-
mental Figures 5–7). Of note, in one 
of our HO models, we used human 
patient–derived FOP cells. This human 
FOP-iPSC–based in vivo FOP model is unique, in that it enabled 
us to test the effect of drug candidates on human patient–derived 
cells in an in vivo environment. However, even though iPSC-based 
in vivo models have several advantages, there are limitations as 
well. For example, they require transplantation of the cells into 
immunodeficient mice, but many types of immune cells contribute 
to the HO in FOP (73). To ensure the importance of mTOR signal-
ing in FOP pathology, we also established FOP-ACVR1 conditional 
transgenic mice. This FOP mouse model confirmed the critical 
role of the mTOR pathway in vivo, although species differences 
should be considered, since FOP-Acvr1 heterozygous mice showed 
perinatal lethality (50). Another important aspect of our study is 
use of a bioactive library that contains currently marketed drugs. 
The fact that rapamycin is an approved drug (46–48) should accel-
erate its future clinical trial for FOP. Interestingly, noting the crit-
ical roles of Hif1α on normal chondrogenesis, Agarwal et al. also 
found that rapamycin decreased extraskeletal bone formation 
by inhibiting HIF1α in 3 HO mouse models (31). Also of note, the 
expression levels of HIF1α and several related downstream genes 
were not upregulated in FOP-iMSCs compared with resFOP- 
iMSCs (Supplemental Figure 11), suggesting that the Hif1α pathway 
is not related to the Activin-A/FOP-ACVR1/mTOR signaling path-
way in FOP-iMSCs, although hypoxia occurs during HO, as dis-
Figure 3. mTOR inhibitors suppress the chondrogenic induction of FOP-iMSCs triggered by Activin-A. (A–
C) Concentration-dependent assays of everolimus, rapamycin, and temsirolimus. 5×A-Luc assay (A), 2DCI 
assay (B), and 3DCI assay (C) in FOP-iMSCs triggered by Activin-A. Cells were harvested 4 days (A), 7 days 
(B), or 21 days (C) after chondrogenesis induction was induced with Activin-A, with or without inhibitors. 
(D and E) Alcian blue staining of FOP-iMSCs in 2DCI (D) and 3DCI (E) assays stimulated by Activin-A. Each 
compound was used at 100 nM. Scale bars: 200 μm (D) and 100 μm (E). Data represent the mean ± SEM. n = 
4 (A) and n = 3 (B and C). Results are representative of at least 2 independent experiments.
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cussed in several studies (31, 32). Another important role of mTOR 
signaling is that of mediating inflammatory responses (74, 75), 
which might have an impact during the early stages of FOP in vivo 
(73). However, our in vitro chondrogenesis induction experiments 
using iMSCs without immune cells clearly showed that mTOR sig-
naling is activated downstream of FOP-ACVR1 signaling (Figure 
6 and Supplemental Figure 8) and that mTOR inhibitors potently 
suppressed the enhanced chondrogenesis of FOP-iMSCs (Figure 3 
Figure 4. Rapamycin suppresses Activin-A–triggered HO in FOP-ACVR1 conditional transgenic mice. Schematic of FOP-ACVR1 (R206H) conditional 
transgenic mice. (B–D) Activin-A injection and oral administration of Dox-induced HO, which was suppressed by i.p. administration of 5 mg/kg rapamycin 
(once daily, 5 times a week) in FOP-ACVR1 transgenic mice. The mice were analyzed 3 weeks after Activin-A injection and rapamycin administration. (B) 
X-ray and μCT findings. (C) Average heterotopic bone volume. (D) Histological analysis of the Activin-A–injected region. H&E, safranin O (acidic proteogly-
can), von Kossa (calcium), and anti-COL1 (bone marker) staining. Scale bars: 10 mm (B) and 100 μm (D). Data represent the mean ± SEM. n = 11 (vehicle or 
rapamycin). ***P < 0.001, by Student’s t test compared with the vehicle-treated group.
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Methods
Cell culture. iPSCs were maintained in primate embryonic stem (ES) 
cell medium (ReproCELL) supplemented with 4 ng/ml recombinant 
human FGF2 (Wako Pure Chemical). To activate the production of 
induced neural crest cells (iNCCs), mTeSR1 medium (STEMCELL 
Technologies) was used for the feeder-free culturing of iPSCs. The 
induction and maintenance of iNCCs and iMSCs derived from iPSCs 
were previously described (43, 45) (Supplemental Figure 1A). Briefly, 
iNCCs were induced in chemically defined medium (CDM) supple-
mented with 10 μM SB-431542 and 1 μM CHIR99021 for 7 days. iNCCs 
and Supplemental Figure 4). We therefore propose that targeting 
mTOR signaling can modulate aberrant FOP-ACVR1 signaling, 
hypoxic signaling, and inflammatory signaling during HO. There-
fore, mTOR inhibitors have the potential to potently suppress HO 
in FOP patients by inhibiting these 3 pathways. Given these seren-
dipitous findings, we believe that rapamycin is a promising drug 
candidate for the treatment of FOP and that an iPSC-based drug 
discovery platform, including iPSC-based HTS and in vivo models, 
offers a remarkable advantage for exploring candidate drugs with a 
higher probability of reaching clinical trials.
Figure 5. Rapamycin suppresses HO derived from FOP-iPSCs in vivo. Administration of 5 mg/kg rapamycin (i.p., once daily, 5 times a week) suppressed 
Activin-A–triggered HO derived from FOP-iMSCs. The mice were analyzed 6 weeks after transplantation and rapamycin administration. (A) X-ray and 
μCT findings. (B) Average heterotopic bone volume. (C) Histological analysis of the cell-transplanted region. H&E, safranin O, von Kossa, anti-COL1, and 
anti-human vimentin staining. Scale bars: 10 mm (A) and 100 μm (C). Results represent the mean ± SEM. n = 5 (vehicle) or 4 (rapamycin). **P < 0.01, by 
Student’s t test compared with the vehicle-treated group. Data are representative of 3 independent experiments.
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Chem Express. SB-431542 and temsirolimus were purchased from 
Sigma-Aldrich. LPA and LY294002 were purchased from Cayman 
Chemical. Ipatasertib and BIRB 796 were purchased from Selleck 
Chemicals. DMH1, HA130, and PF-8380 were purchased from Tocris 
Bioscience, EMD Millipore, and Ark Pharm, respectively. Activin-A, 
BMP-7, and TGF-β3 were dissolved according to the manufacturer’s 
protocols and used at 100 ng/ml (Activin-A and BMP-7) or 10 ng/ml 
(TGF-β3), unless otherwise noted.
Chemical libraries. All chemical libraries were purchased from the 
suppliers listed in Table 1. All compounds were bioactive and/or anno-
tated, with the exception of compounds from Analyticon Discovery, 
which mainly includes natural compounds.
Generation of FOP-5×A-Luc-iPSCs. Luciferase (luc+; Promega) 
following the COL2A1 promoter and 5-repeats Aggrecan enhancer (49) 
was inserted into pTrans1-3 (76), which enabled us to easily produce sta-
bly expressing cell lines using Tol2 transposase from Japanese medaka 
fish (Oryzias latipes) (77, 78) (pTrans1-3/5×A-Luc, Figure 1A). pTrans1-3/ 
5×A-Luc and pCAGGS-mT2TP (Tol2 transposase expression vec-
tor) were cotransfected into FOP-iPSCs by FuGENE HD (Prome-
ga) according to the manufacturer’s protocol, and the neomycin- 
resistant clone (100 μg/ml) was selected and used as FOP-5×A- 
Luc-iPSCs. pTrans1-3 included SAR-CH4, an insulator module from 
were maintained in CDM supplemented with 10 μM SB-431542, 20 
ng/ml FGF2, and 20 ng/ml recombinant human EGF (R&D Systems), 
and we used up to 20 passages in this study. iMSCs were induced and 
maintained in αMEM (Invitrogen, Thermo Fisher Scientific) sup-
plemented with 10% (v/v) FBS (Nichirei), 5 ng/ml FGF2, and 0.5% 
penicillin and streptomycin (Invitrogen, Thermo Fisher Scientific). 
The FOP-iPSCs used in this study (previously described as vFOP4-1 
[ref. 44]) harbor the R206H heterozygous mutation in ACVR1, and 
gene-corrected resFOP-iPSCs were generated by BAC-based homol-
ogous recombination. These cells fulfilled several criteria for iPSCs 
including the expression of pluripotent markers, teratoma forma-
tion, normal karyotype, and morphology. Growth and gene expres-
sion profiles of the resFOP-iPSC clones were indistinguishable from 
the original FOP-iPSCs (45). However, remarkably distinct respon-
siveness to Activin-A was observed (38). Murine multipotent mesen-
chymal C3H10T1/2 cells expressing Dox-inducible human INHBA 
(C3H-DoxOn-hINHBA) were maintained in DMEM (Nacalai Tesque) 
supplemented with 10% FBS and 1 mM Na-pyruvate (Thermo Fisher 
Scientific) and used for an Activin-A–induced HO model transplanted 
with FOP-iMSCs as previously reported (38).
Reagents. Activin-A, BMP-7, and TGF-β3 were purchased from 
R&D Systems. Rapamycin and everolimus were purchased from Med-
Figure 6. Enhanced mTOR signaling in chondrogenic induc-
tion of FOP-iMSCs. (A and B) Knockdown experiments of 
mTORC complex components assessed by GAG/DNA (A) and 
Alcian blue staining (B) in a 2DCI assay of FOP-iMSCs. Scale 
bar: 200 μm. (C and D) Phosphorylation of SMAD1/5/8 (C) 
and SMAD2/3 (D) in FOP-iMSCs. Serum-starved FOP-iMSCs 
were pretreated with 10 nM rapamycin (Rapa), 1 μM DMH1, or 
1 μM SB-431542 for 1 hour, and after a 1-hour stimulation with 
Activin-A, the cells were harvested. (E) p-S6 was enhanced 
in FOP-iMSCs compared with resFOP-iMSCs In 2DCI assays, 
p-S6 was enhanced in Activin-A–stimulated FOP-iMSCs 
compared with levels detected in resFOP-iMSCs. The strength 
of resFOP at each time point was set at 1. (F) Enhanced p-S6 
was inhibited by mTOR (Rapa), PI3K (LY), or AKT (Ipa) inhib-
itors 24 hours after treatment with Activin-A and inhibitors 
in FOP-iMSCs. Treatment with 10 μM DMH1, 10 μM BIRB 796 
(BIRB), 10 μM LY294002 (LY), 1 μM ipatasertib (Ipa), or 10 nM 
rapamycin was used. Results represent the mean ± SEM.  
n = 3 (A and C–F). *P < 0.05, **P < 0.01, and ***P < 0.001, by 
Dunnett’s multiple comparisons t test compared with the 
DMSO-treated control stimulated with Activin-A (C, D, and F); 
with the siRNA-transfected negative control, with or without 
Activin-A stimulation (A); and by Student’s t test compared 
with resFOP-iMSCs stimulated with Activin-A (E). Data are 
representative of 2 independent experiments (A, B, E, and F).
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screened compounds are given as the percentage of 
inhibition, which was calculated using the following 
equation: (1 – [relative luciferase units (RLU) of com-
pound] – [RLU of minimum [min]]/([RLU of maxi-
mum [max]] – [RLU of min]) × 100, where (RLU of 
max) and (RLU of min) are the mean of the RLU of 
the DMSO control and 10 μM SB-431542, respec-
tively. The Z-factor, which is widely used as a mea-
sure of the assay quality of each plate, was calculated 
using the following equation: Z-factor = 1 – 3 × ([SD of 
max] + [SD of min])/([RLU of max] – [RLU of min]) 
(Supplemental Figure 1C). The average Z-factor over 
22 plates in the HTS assay was 0.62, indicating the 
accuracy and reliability of the HTS campaign (gen-
eral criteria: HTS >0.50) (79). The S/B ratio was 
calculated using the following equation: ([RLU of 
max]/[RLU of min]) (Supplemental Figure 1D). The 
average S/B ratio over 22 plates in the HTS assay was 
3.9, also indicating the accuracy and reliability of the 
HTS campaign (general criteria: HTS >3.0). alamar-
Blue Cell Viability Reagent (Thermo Fisher Scien-
tific) was used to eliminate toxic compounds in the 
second screening.
Using the 5×A-Luc assay, the first screening (n = 1, 
1 μM) was performed against an HTS library, which 
contained 6,809 small-molecule compounds. As a 
result of the first screening, 549 hit compounds were 
obtained (criteria: >40% inhibition of DMSO con-
trol stimulated with Activin-A). A second screening 
was performed against these 549 compounds (n = 2; 
test compounds = 0.01, 0.1, and 1 μM), and 76 hit 
compounds were obtained (criteria: IC50 <1 μM in the 
5×A-Luc assay and inhibition of <20% at any dose in 
the alamarBlue assay). Through the classification of the 
76 hit compounds, we focused on mTOR signaling, as 
mentioned in the Results section.
2DCI and 3DCI. Chondrogenesis induction 
was performed, and differentiation properties were 
assayed as previously described (38, 80, 81). The 
chondrogenic medium (with 100 ng/ml Activin-A 
and inhibitors, unless otherwise noted) was changed 
every 2 to 3 days until day 7 (2DCI) or until days 
14–21 (3DCI), unless otherwise indicated. Gene- 
specific siRNAs were purchased from Thermo Fisher Scientific 
(Silencer Select Predesigned siRNA). For the transient expression of 
siRNA, Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientif-
ic) was used according to the manufacturer’s instructions. Sequence 
information and knockdown efficiencies are shown in Supplemental 
Figure 12 and Supplemental Table 6.
Generation of human FOP-ACVR1 conditional transgenic mice. 
FOP-ACVR1 conditional transgenic mice were generated according 
to previously reported methods (82–84). Briefly, FOP-ACVR1, fol-
lowed by IRES-mCherry, was targeted into the 3′-UTR region of the 
Col1a1 gene locus under the tetracycline-dependent promoter of KH2 
ES cells, which harbor the optimized reverse tetracycline–dependent 
transactivator at the ROSA26 locus (83, 84). After germline trans-
mission was confirmed, heterozygous ROSA26::M2rtTA mice with a 
human IFN–β scaffold attachment region and chicken β-globin DNase 
I hypersensitive site 4, and Tol2 (5′) or (3′), active transposable Tol2 
elements. pCAGGS-mT2TP is an expression plasmid containing the 
Tol2 transposase cDNA whose codons are optimized for mammals 
under the control of the CAG promoter.
HTS. iMSCs differentiated from FOP-5×A-Luc-iPSCs were plated 
in 384-well white plates (40,000 cells/well/90 μl; BD Biosciences) in 
chondrogenic medium (38) containing 100 ng/ml Activin-A. After the 
addition of 10 μl of test compounds (final, 1 μM), the assay plates were 
incubated at 37°C under 5% CO2 (Supplemental Figure 1B). After 4 
days of incubation, luciferase activity was measured using the Bright-
Glo Luciferase Assay System (Promega) according to the manufac-
turer’s protocol. The resultant luminescent signal was measured on 
PowerScan 4 (DS Pharma Biomedical). The inhibitory effects of the 
Figure 7. ENPP2 mediates enhanced mTOR signaling in chondrogenic induction of FOP- 
iMSCs. (A) Venn diagram of genes highly upregulated in FOP-iMSCs compared with res-
FOP-iMSCs 24 hours after chondrogenesis induction stimulated with Activin-A, BMP-7, or 
TGF-β3. (B) Genes highly upregulated in FOP-iMSCs 24 hours after chondrogenesis induction 
stimulated with Activin-A, but not with BMP-7 or TGF-β3. (C) Expression of ENPP2 during the 
chondrogenic induction of FOP-iMSCs and resFOP-iMSCs. The expression level of resFOP (0 h) 
was set at 1. (D and E) ENPP2 inhibitors (HA, HA130; PF, PF-8380) (D) and ENPP2 knockdown 
(E) reduced p-S6 levels. (D) The cells were harvested 24 hours after treatment with Activin- 
A and ENPP2 inhibitors, and (E) siRNA–transfected cells were harvested 48 hours after 
treatment with Activin-A. Rapa, 100 nM rapamycin; HA, 10 μM HA130; PF, 10 μM PF-8380. (F) 
Serum-starved FOP-iMSCs were treated with 100 μM LPA, and 30 minutes after stimulation, 
the cells were harvested. Results represent the mean ± SEM. n = 1 (A and B) and n = 3 (C–F).  
*P < 0.05, **P < 0.01, and ***P < 0.001, by Student’s t test compared with LPA (–) control (F), 
by Dunnett’s multiple comparisons t test compared with FOP-iMSCs stimulated with Activin- 
A (D), or with negative control siRNA-transfected FOP-iMSCs stimulated with Activin-A (E). 
Data are representative of 2 independent experiments (D and F).
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von Kossa, safranin O, human-specific anti-vimentin antibody, or col-
lagen I antibody as previously described (38, 80, 85).
Quantitative PCR analysis. Total RNA was purified with an RNeasy 
Kit (QIAGEN) and treated with a DNase-One Kit (QIAGEN) to remove 
genomic DNA. Total RNA (0.3 μg) was reverse transcribed for single- 
stranded cDNA using random primers and Superscript III Reverse 
Transcriptase (Thermo Fisher Scientific) according to the manufac-
turer’s instructions. Quantitative PCR (qPCR) was performed with 
Thunderbird SYBR qPCR Mix (TOYOBO) and analyzed with the 
StepOne Real-Time PCR System (Applied Biosystems). The primer 
sequences are described in Supplemental Table 7. 3D chondrogenic 
differentiated pellets were homogenized using a Multi-Beads Shock-
er (Yasui Kikai) according to the manufacturer’s instructions. All data 
(relative expression) were corrected by β-actin.
Microarray experiments. 2D chondrogenesis induction was per-
formed in FOP- and resFOP-iMSCs stimulated with 100 ng/ml 
Activin-A, 100 ng/ml BMP-7, or 10 ng/ml TGF-β3, and after incubation 
for 6, 24, or 48 hours or 7 days, mRNA was extracted. RNA was reverse 
transcribed, biotin labeled, and hybridized to the GeneChip Human 
Gene 1.0 ST Expression Array (Affymetrix), which was subsequently 
washed and scanned according to the manufacturer’s instructions. 
Raw CEL files were imported into GeneSpring GX 12.6.1 software 
(Agilent Technologies), and the expression values were calculated with 
the RMA16 algorithm. Pathway analysis was performed using Inge-
nuity Pathway Analysis (QIAGEN). Array data were deposited in the 
NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE90638).
Western blotting. SDS-PAGE and blotting with whole-cell lysates 
were performed by standard procedures. Protein bands were detected 
with ECL Prime Western Blotting Detection Reagent (GE Healthcare) 
and visualized using the Bio-Rad Molecular Imager Chemi-Doc XRS+ 
with Image Lab software (Bio-Rad). The antibodies used in this study 
are described in Supplemental Table 8. All data (relative intensity) 
were corrected by β-actin or total SMADs.
GAG value. GAG content was quantified in pellets with the Blyscan 
Glycosaminoglycan Assay Kit (Biocolor). DNA content was quantified 
using the PicoGreen dsDNA Quantitation Kit (Thermo Fisher Scientific).
IHC. Paraffin-embedded sections were deparaffinized, and for 
human-specific anti-vimentin antibody, antigen retrieval was per-
formed by autoclaving (105°C, 10 min). Samples were blocked with 
Blocking One (Nacalai Tesque) for 60 minutes and then incubat-
ed with human-specific anti-vimentin antibody (Abcam) or anti– 
collagen I antibody (Novus Biologicals) diluted in Can Get Signal 
Immunostain Solution B (Toyobo) for 16 to 18 hours at 4°C. Next, sam-
ples were washed several times in 0.2% Tween-20 (Sigma-Aldrich) in 
PBS and incubated with goat anti-rabbit IgG (H+L) secondary anti-
body or Alexa Fluor 488 or Alexa Fluor 555 conjugate (Thermo Fisher 
Scientific) diluted in Can Get Signal Immunostain Solution B for 1 
hour at room temperature. DAPI (10 μg/ml) was used to counterstain 
nuclei. Samples were observed by BZ-9000E (KEYENCE).
Statistics. The statistical significance of all experiments was cal-
culated using 2-tailed Student’s t test or 1-way ANOVA for Dunnett’s 
multiple comparisons t test. All statistical tests were performed using 
GraphPad Prism 6 (GraphPad Software). P values of less than 0.05 
were considered statistically significant.
Study approval. All experimental protocols dealing with human 
subjects were approved by the ethics committee of the Department of 
Medicine and Graduate School of Medicine of Kyoto University. Written 
heterozygous tetO-FOP-ACVR1 allele were used to induce the FOP-
ACVR1 gene. Genomic DNA was extracted from the tail of each mouse 
using a DNeasy Blood and Tissue Kit (QIAGEN) and subjected to 
genotype analysis. PCR was performed using KOD -Plus- Neo (TOYO-
BO) according to the manufacturer’s instructions. The following PCR 
primers were used: for Col1a1::FOP-ACVR1: oIMR6724_Col1-FOP, 
CCTCCATGTGTGACCAAGG; oIMR6725_Col1-FOP, GCACAG-
CATTGCGGACATGC; and oIMR6726_Col1-FOP, GCAGAAGCG-
CGGCCGTCTGG; for ROSA26::M2rtTA: oIMR8052_Rosa-tetO, 
GCGAAGAGTTTGTCCTCAACC; oIMR8545_Rosa-tetO, AAAGTC-
GCTCTGAGTTGTTAT; and oIMR8546_Rosa-tetO, GGAGCGG-
GAGAAATGGATATG.
Cardiotoxin-induced HO model in human FOP-ACVR1 conditional 
transgenic mice. Female mice (filial generations 3–5 [F3–F5] offspring 
of chimeric mice, age- and BW-matched between groups) were used 
between 16 and 21 weeks of age. Mice were administered 2 mg/ml Dox 
in their drinking water supplemented with 10 mg/ml sucrose to induce 
FOP-ACVR1. Cardiotoxin (9.1 μg/mouse; latoxan) was injected into 
the right gastrocnemius muscle to initiate skeletal muscle injury and 
subsequent heterotopic bone formation (50). Rapamycin (16% DMSO 
in 0.5 w/v% methylcellulose 400 cP) was administered i.p. once a day, 
5 times a week. Mice were analyzed 4 weeks after injection. For x-ray 
images, mice were anesthetized with isoflurane (5% for induction, 
2%–3% for maintenance; Abbvie), immobilized, and x-rayed using 
μFX-1000 (Fujifilm) or DX-50 (Faxitron Bioptics). μCT images were 
scanned using x-ray CT systems (inspeXio SMX-100CT; Shimadzu) 
and analyzed by TRI/3D-BON software (Ratoc System Engineering) 
according to the manufacturer’s instructions. Four weeks after injec-
tion, the injected sites were harvested, fixed with 4% paraformalde-
hyde for twenty-four hours, embedded in paraffin, and sectioned and 
stained with H&E, von Kossa, safranin O, or anti–collagen I antibody 
as previously described (38, 80).
Activin-A–induced HO model in human FOP-ACVR1 conditional 
transgenic mice. Male mice (F3–F5 offspring of chimeric mice, age- and 
BW-matched between groups) were used between 13 and 14 weeks of 
age. Activin-A (13.3 μg/mouse) was injected into the right gastrocne-
mius muscle to initiate skeletal muscle injury and subsequent hetero-
topic bone formation. Rapamycin (16% DMSO in 0.5 w/v% methyl-
cellulose 400) was administered i.p. once a day, 5 times a week. Mice 
were analyzed 3 weeks after injection.
BMP-7–induced HO model mice. BMP-7 (2 μg/mouse) was injected 
into the right gastrocnemius muscle of 6- to 8-week-old male 
C57BL/6NJcl mice (CLEA Japan), and compounds were administered 
once a day, 5 times a week (orally), or every day (i.p.). Mice were ana-
lyzed 11–16 days after injection.
Activin-A–induced HO model transplanted with FOP-iMSCs. FOP- 
(right leg) and resFOP-iMSCs (left leg) (4 × 106 cells, respectively) 
were transplanted into the gastrocnemius muscle of 6- to 8-week-old 
NOD/ShiJic-scid Jcl (NOD/SCID) mice (CLEA Japan) with C3H-Dox-
On-hINHBA (5 × 105 cells), which can continuously expose Activin-A 
to the transplanted iMSCs in vivo (38). In the Dox-induced group, 1 
mg/ml Dox (Sigma-Aldrich) was administered via the drinking water 
with 10 mg/ml sucrose (Nacalai Tesque) for 2 weeks after transplanta-
tion. Compounds were administered i.p. or orally once a day, 5 times 
a week. Six to eight weeks after transplantation, the transplanted cells 
were harvested, fixed with 4% paraformaldehyde for twenty-four 
hours, embedded in paraffin, and sectioned and stained with H&E, 
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